Swiss Group of Clinical Cancer Research (SAKK)
Cost-effectiveness of nivolumab in the treatment of head and neck cancer
Hirschmann A, Lupatsch J, Schwenkglenks M, Panje C, Matter-Walstra K, Espeli V, Dedes K, Siano M, Swiss Group of Clinical Cancer Research (SAKK). Cost-effectiveness of nivolumab in the treatment of head and neck cancer. Oral Oncol 2018; 87:104-110.
Oct 30, 2018Cost-effectiveness of nivolumab in the treatment of head and neck cancer
Oct 30, 2018Oral Oncol 2018; 87:104-110
Hirschmann A, Lupatsch J E, Schwenkglenks M, Panje Cédric, Matter-Walstra K, Espeli V, Dedes K J, Siano Marco, Swiss Group of Clinical Cancer Research (SAKK)
Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99)
Hess D, Goldhirsch A, Castiglione-Gertsch M, Rufener B, Ballabeni P, Rauch D, Aebi S, Pagani O, Thürlimann B, Swiss Group of Clinical Cancer Research (SAKK). Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004; 15:1760-5.
Dec 1, 2004Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99)
Dec 1, 2004Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004; 15:1760-5
Hess Dagmar, Goldhirsch A, Castiglione-Gertsch M, Rufener B, Ballabeni P, Rauch D, Aebi S, Pagani O, Thürlimann Beat, Swiss Group of Clinical Cancer Research (SAKK)